Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galectin Therapeutics Inc.

http://www.galectintherapeutics.com

Latest From Galectin Therapeutics Inc.

Analysts Impressed By Amryt As EB Drug Action Date Approaches

Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.

Business Strategies Rare Diseases

Gilead’s Long-Acting HIV Drug Among Latest EU Filings

The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.

Europe Drug Review

Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU

The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.

Europe Drug Review

Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings

Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.

Europe Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Other Names / Subsidiaries
    • Galectin Sciences, LLC
    • Pro-Pharmaceuticals Inc.
    • Galectin Therapeutics Security Corp.
UsernamePublicRestriction

Register